The early clinical trial results of BSABs against PD-1/LAG-3 also offer new therapeutic prospects for managing patients with R/R DLBCL, albeit with a slightly lower CR (9%) [46]. Here, LAG3 is linked to diffuse large B-cell lymphoma.